The Massachusetts General Hospital Cancer Center announced that Central Maine Healthcare Oncology Social Workers Karen DeGrandpre, LCSW, OSW-c and Kailie Sullivan, LCSW, OSW-c have been selected as honorees of the one hundred 2017.
the one hundred is an awareness and fundraising initiative created and supported by the Mass General Cancer Center celebrating hope in the cancer community by honoring 100 Everyday Amazing individuals who are making a difference in the fight against cancer in inspiring and often revolutionary ways. Being selected as part of the one hundred is one of the highest forms of recognition from the Mass General Cancer Center.
“[DeGrandpre] and [Sullivan] are central to ensuring each patient and family get the help they need, often through direct counseling or referrals to community resources. We serve a socioeconomically disadvantaged and large, rural population with patients often traveling an hour or more to their treatments. [DeGrandpre] and [Sullivan] take the lead in providing a transportation plan and hands on management of insurance, financial, and work-related issues, often serving as the liaisons between the patients, their care team, and the financial counseling program.,” said Courtney Jensen, M.D., Medical Director of Radiation Oncology.
In addition to their work as liaisons, DeGrandpre and Sullivan have integrated distress management into the center’s cancer program to track the impact of distress and outcomes in the cancer population. “[DeGrandpre] and [Sullivan] are truly one-in-a-million for the work they do every day helping to meet the needs of cancer patients in central Maine,” continued Jensen.
DeGrandpre and Sullivan will be recognized at the one hundred 10th annual dinner on Thursday, June 15, 2017 at the Westin Boston Waterfront Hotel in Boston. The evening’s events will feature a selection of honoree stories and highlight the groundbreaking work that will contribute to conquering cancer. The funds raised through the one hundred support Mass General Cancer Center’s research into immunotherapies, targeted therapies and early-detection technologies, as well as innovative supportive care programs.